EDIT 10-Q: SEC filing
Editas Medicine
Filed with the SEC on · accession 0001650664-26-000103
EDIT filed a 10-Q (quarterly report) with the SEC on Nov 9, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +7.6% by the first close after the filing.
Summary of the filing
Editas Medicine filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing routine financial results, cash position, and recent financing activities including an underwritten offering and an at-the-market facility.
Key details
How EDIT stock reacted
Close before
$2.57
Nov 6, 2026
First close after
+7.59%
$2.77
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for EDIT, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for EDIT?
Click hereFrequently asked questions
What did EDIT file with the SEC on Nov 9, 2026?
EDIT filed a 10-Q (SEC filing). Editas Medicine filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing routine financial results, cash position, and recent financing activities including an underwritten offering and an at-the-market facility.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did EDIT stock react to this filing?
EDIT closed at $2.57 before the filing and $2.77 on Nov 9, 2026 (+7.59%).
Other EDIT SEC filings
- 8-K · SEC filingNov 9, 2026
- SCHEDULE 13G · SEC filingOct 27, 2026
- 8-K · Fda approvalOct 8, 2026
- S-3 · Shelf registrationAug 31, 2026
- SCHEDULE 13G · SEC filingAug 14, 2026
- 8-K · Board changeAug 5, 2026
- 10-Q · SEC filingAug 5, 2026
- 8-K · Board changeJun 18, 2026
- 144 · Insider sale plannedMay 29, 2026
- 8-K · SEC filingMay 26, 2026
Get alerts when EDIT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days